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The truncated non-signaling ghrelin receptor growth hor-
mone secretagogue R1b (GHS-R1b) has been suggested to sim-
ply exert a dominant negative role in the trafficking and signal-
ing of the full and functional ghrelin receptorGHS-R1a.Herewe
reveal a more complex modulatory role of GHS-R1b. Differen-
tial co-expression of GHS-R1a and GHS-R1b, both in HEK-
293T cells and in striatal and hippocampal neurons in culture,
demonstrates that GHS-R1b acts as a dual modulator of GHS-
R1a function: low relative GHS-R1b expression potentiates and
high relativeGHS-R1bexpression inhibitsGHS-R1a functionby
facilitating GHS-R1a trafficking to the plasma membrane and
by exerting a negative allosteric effect on GHS-R1a signaling,
respectively. We found a preferential Gi/o coupling of the GHS-
R1a-GHS-R1b complex in HEK-293T cells and, unexpectedly, a
preferential Gs/olf coupling in both striatal and hippocampal
neurons in culture. A dopamine D1 receptor (D1R) antagonist
blocked ghrelin-induced cAMP accumulation in striatal but not
hippocampal neurons, indicating the involvement of D1R in the
striatal GHS-R1a-Gs/olf coupling. Experiments in HEK-293T
cells demonstrated thatD1Rco-expressionpromotes a switch in
GHS-R1a-G protein coupling from Gi/o to Gs/olf, but only upon
co-expression of GHS-R1b. Furthermore, resonance energy
transfer experiments showed that D1R interacts with GHS-R1a,
but only in the presence of GHS-R1b. Therefore, GHS-R1b not
only determines the efficacy of ghrelin-induced GHS-R1a-me-
diated signaling but also determines the ability of GHS-R1a to
form oligomeric complexes with other receptors, promoting
profound qualitative changes in ghrelin-induced signaling.
Ghrelin is an orexigenic hormone, an internal signal for the
animal to engage in food-directed behavior (1, 2). It is produced
by stomach oxyntic cells, which provide plasma levels that fluc-
tuate diurnally with a peak in the day and trough at night. Nota-
bly, oxyntic cells qualify as food-entrained oscillators, and ghre-
lin plasma levels increase during anticipated mealtimes and
decrease aftermeals (1). These and other lesswell characterized
central neuronal functions of ghrelin depend on its ability to
cross the blood-brain barrier by still unclear mechanisms and
reaching ghrelin receptors localized in specific brain areas, such
as the hypothalamus, hippocampus, amygdala, mesencephalic
dopaminergic regions, and striatum (2–4).
Ghrelin acts on the class A G protein-coupled receptor
known as growth hormone secretagogue (GHS)5 receptor or
GHS-R1a. Cells expressing GHS-R1a also express GHS-R1b,
a truncated variant of GHS-R1a lacking transmembrane
domains 6 and 7. Ghrelin does not bind and therefore does not
signal throughGHS-R1b (5), and the role of this truncated “recep-
tor” on ghrelin-mediated signaling is just beginning to be under-
stood. Evidence has been provided for the ability of GHS-R1a to
homodimerize and heterodimerize with GHS-R1b, which might
allow GHS-R1b to produce a dominant negative effect on GHS-
R1a signaling. Two different mechanisms have been invoked for
the dominant negative function of GHS-R1b: intracellular reten-
tion by an inability ofGHS-R1b to traffic to the plasmamembrane
(6, 7) and an allostericmechanism that produces a conformational
block of GHS-R1a in a non-signaling conformation (5). Those
resultswereobtained from invitroexperiments in transfectedcells
and in reconstituted lipid vesicles, and, therefore, either mecha-
nism could be involved in a physiological cellular environment.
However, although both mechanisms do not seem exclusive, the
intracellular retention of the GHS-R1a-GHS-R1b heteromer
would render the reported complete blockade ofGprotein activa-
tion and -arrestin recruitment (5) a fortuitous useless mecha-
nism because both signaling pathways originate in the plasma
membrane. The initial aimof this studywas elucidating themech-
anisms of GHS-R1b-mediated modulation of GHS-R1a in a neu-
ronal environment and includes signaling experiments performed
in a mammalian cell line and primary neurons in culture, with
particular emphasis on the changes produced by manipulation of
the relative expression of GHS-R1a and GHS-R1b in the plasma
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membrane. The study reveals a significant and complex modula-
tory role of GHS-R1b in the trafficking and signaling of GHS-R1a
that depends on the relative expression of both proteins. Anunex-
pected additional finding in striatal and hippocampal neurons in
culture was a predominant Gs/olf protein-dependent signaling of
ghrelin that, in striatal neurons, depended on dopamineD1 recep-
tor (D1R)-GHS-R1a-GHS-R1b heteromerization.
Experimental Procedures
Cell Lines and Neuronal Primary Cultures—HEK-293T cells
were grown in DMEM (Gibco) supplemented with 2 mM L-glu-
tamine, 100 g/ml sodium pyruvate, 100 units/ml penicillin/
streptomycin, minimum Eagle’s medium non-essential amino
acid solution (1/100) and 5% (v/v) heat-inactivated FBS (all sup-
plements were from Invitrogen). Primary cultures of striatal,
hippocampal, and cortical neurons were obtained from fetal
Sprague-Dawley rats (embryonic day 19). Cells were isolated as
described in Ref. 8 and plated at a confluence of 40,000 cells/
0.32 cm2 in 96-well plates forMAPK experiments and in 6-well
plates for the other assays. Cells weremaintained inNeurobasal
medium supplemented with 2 mM L-glutamine, 100 units/ml
penicillin/streptomycin, and 2% (v/v) B27 supplement (Gibco)
in a 96-well plate for 12 days.
Vectors and Fusion Proteins—Sequences encoding amino
acid residues 1-155 and 155-238 of the Venus variant of YFP
and amino acid residues 1-229 and 230-311 of Rluc8 protein
were subcloned in the pcDNA3.1 vector to obtain YFP andRluc
hemitruncated proteins. Human cDNAs for GHS-R1a, GHS-
R1b, cannabinoid CB1 receptor (CB1R), corticotropin-releas-
ing factor CRF1 receptor (CRF1R), or adenosine A1 receptor
(A1R), cloned into pcDNA3.1, were amplified without their
stop codons using sense and antisense primers harboring EcoRI
and KpnI sites to clone GHS-R1a, GHS-R1b and CRF1R in the
pRLuc-N1 vector (pRLuc-N1, PerkinElmer Life Sciences) or in
the pEYFP-N1 vector (enhanced yellow variant of GFP, Clon-
tech); HindIII and BamHI sites to clone A1R in the
pcDNA3.1cRluc8- vector; BamHI and EcoRI sites to clone
CB1R in the pcDNA3.1RLuc vector; or EcoRI and KpnI sites to
cloneGHS-R1a receptors in aGFP2-containing vector (p-GFP2,
Packard BioScience, Meridien, CT). Amplified fragments were
subcloned to be in-frame with restriction sites of pRLuc-N1,
pEYFP-N1, or p-GFP2 vectors to provide plasmids that express
proteins fused to RLuc, YFP, or GFP2 on the C-terminal end
(GHS-R1a-Rluc, GHS-R1b-Rluc, CB1R-Rluc, CRF1R-Rluc,
GHS-R1a-YFP, GHS-R1b-YFP, or GHS-R1a-GFP2). For biolu-
minescence resonance energy transfer (BRET) with bimolecu-
lar fluorescence and luminescence complementation (BiFC and
BiLC) experiments, cDNA for GHS-R1b was subcloned into
pcDNA3.1-nVenus and cDNA for GHS-R1a was subcloned
into pcDNA3.1-cVenus to provide plasmids that express the
receptor fused to the hemitruncated nYFP Venus or cYFP
Venus on the C-terminal end of the receptor (GHS-R1b-nYFP
and GHS-R1a-cYFP). Also, the cDNA for GHS-R1b was sub-
cloned into pcDNA3.1-nRluc8 and the cDNA forGHS-R1a and
A1R were subcloned into pcDNA3.1-cRluc8 to provide plas-
mids that express the receptor fused to the hemitruncated
nRluc8 or cRluc8 on the C-terminal end of the receptor (GHS-
R1b-nRluc, GHS-R1a-cRluc, and A1R-cRluc).
Cell Transfection—HEK-293T cells and neuronal primary
cultures growing in 6-well dishes were transiently transfected
with the corresponding protein cDNA by the PEI (Sigma-Al-
drich, St. Louis, MO) method. Cells were incubated (4 h for
HEK-293T cells and 6 h for neurons) with the corresponding
cDNA togetherwith PEI (5.47mM innitrogen residues) and 150
mM NaCl in a serum-starved medium. After 4 h, the medium
was changed to a fresh complete culture medium. Forty-eight
hours after transfection, cells were washed twice in quick suc-
cession in Hanks’ balanced salt solution with 10 mM glucose,
detached, and resuspended in the same buffer. Cells weremain-
tained at 37 °C in an atmosphere of 5% CO2.
Resonance Energy Transfer-based Assays—For BRET assays,
HEK-293T cells were transiently co-transfectedwith a constant
cDNA encoding for receptor-Rluc and with increasing
amounts of cDNA corresponding to receptor-YFP or receptor-
GFP2. To control the cell number, the sample protein concen-
tration was determined using a Bradford assay kit (Bio-Rad)
using bovine serumalbumin dilutions as standards. To quantify
fluorescence proteins, cells (20 g protein) were distributed in
96-well microplates (black plates with a transparent bottom),
and the fluorescence was read in a Fluostar Optima fluorimeter
(BMG Labtech, Offenburg, Germany) equipped with a high-
energy xenon flash lamp using a 10-nm bandwidth excitation
filter at 410 nm for receptor-GFP2 reading or 485 nm for recep-
tor-YFP reading. Receptor fluorescence expression was deter-
mined as fluorescence of the sample minus the fluorescence of
cells expressing receptor-Rluc alone. For BRETmeasurements,
the equivalent of 20 g of cell suspension was distributed in
96-well white microplates with white bottoms (Corning 3600,
Corning, NY) and 5M of coelenterazine H (for the YFP accep-
tor) or DeepBlueC (for the GFP2 acceptor) (Molecular Probes,
Eugene, OR) were added. Using DeepBlueC or coelenterazine
H as substrates results in respective 410- and 485-nm emissions
fromRluc, which allows the respective selective energy transfer
to GFP2 and YFP (14). One minute after adding coelenterazine
H or immediately after addition of DeepBlueC, BRET was
determined using a Mithras LB 940 reader (Berthold Technol-
ogies, DLReady), which allows the integration of the signals
detected in the short-wavelength filter at 485 nm and the long-
wavelength filter at 530 nm when YFP is the acceptor or the
short-wavelength filter at 400 nm and the long-wavelength fil-
ter at 510 nmwhen GFP2 is the acceptor. To quantify receptor-
Rluc expression, luminescence readings were performed after
10 min of adding 5 M of coelenterazine H irrespective of the
acceptor used. Net BRET is defined as [(long-wavelength emis-
sion)/(short-wavelength emission)]  Cf, where Cf corre-
sponds to [(long-wavelength emission)/(short-wavelength
emission)] for the Rluc construct expressed alone in the same
experiment. For BiFC and BiLC assays, HEK-293T cells were
transiently co-transfected with a constant amount of cDNA
encoding for proteins fused to nRLuc8 or cRLuc8 and with
increasing amounts of the cDNA corresponding to proteins
fused to nYFP Venus or cYFP Venus. The complemented YFP
Venus or Rluc8 expression and BRET were quantified as
described above. For sequence resonance energy transfer
(SRET) assays (14), HEK-293T cells were transiently co-trans-
fected with constant amounts of cDNAs encoding for both the
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receptor fused to RLuc or GFP2 and with increasingly amounts
of cDNA corresponding to the receptor fused to YFP. Using
aliquots of transfected cells (20 g of protein), different deter-
minations were performed in parallel: quantification of pro-
tein-YFP expression and quantification of protein-Rluc expres-
sion as described above. For SRET, cells were distributed in
96-well microplates, and 5 M DeepBlueC was added. The
SRET signal was collected using a Mithras LB 940 reader with
detection filters for short wavelength (410 nm) and long wave-
length (530 nm). By analogy with BRET, net SRET is defined as
((long wavelength emission)/(short wavelength emission)) 
Cf, where Cf corresponds to long wavelength emission / short
wavelength emission for cells expressing protein-Rluc and pro-
tein-GFP2. Linear unmixing was done for SRET quantifica-
tion, taking into account the spectral signature to separate
the two fluorescence emission spectra (11). SRET is
expressed as milliSRET units (mSU; net SRET 1000).
Immunocytochemistry—Transiently transfected HEK-293T
cells were fixed in 4% paraformaldehyde for 15min andwashed
with PBS containing 20 mM glycine (buffer A) to quench the
aldehyde groups. After permeabilizationwith buffer A contain-
ing 0.2% Triton X-100 for 5 min, cells were treated with PBS
containing 1% bovine serum albumin. After 1 h at room tem-
perature, cells expressing receptor-Rlucwere labeledwith a pri-
mary mouse monoclonal anti-Rluc antibody (1/100, EMDMil-
lipore, Darmstadt, Germany) for 1 h, washed, and stained with
a secondary antibody for Cy3 donkey anti-mouse (1/100, Jack-
son ImmunoResearchLaboratories, Baltimore,MD). Receptors
fused to YFP were detected by their fluorescence properties.
Samples were rinsed and observed under a Leica SP2 confocal
microscope or an SP5 confocal microscopy for DsRed (Leica
Microsystems, Mannheim, Germany).
Western Blotting—To determine the GHS-R1a-YFP, GHS-
R1b-YFP, or CB1R-YFP expression levels in transfected HEK-
293T cells, equivalent amounts of cell protein (10 g) were
separated by electrophoresis on a denaturing 10% SDS-poly-
acrylamide gel and transferred onto PVDF fluorescence mem-
branes. Themembraneswere probedwith amixture of amouse
anti--tubulin antibody (1:2000, Sigma-Aldrich) and a rabbit
anti-YFP antibody (1:1000, Santa Cruz Biotechnology, Dallas,
TX) and a mixture of IRDye 800 (anti-mouse) antibody
(1:10,000; Sigma-Aldrich) and IRDye 680 (anti-rabbit) antibody
(1:10,000; Sigma). Bands were scanned using an Odyssey infra-
red scanner (LI-COR Biotechnology, Lincoln, NE). Band den-
sities were quantified using the scanner software, and the
receptor level was normalized for differences in loading using
tubulin protein band intensities.
Biotinylation Experiments—Cell surface proteins were bioti-
nylated as described previously (9) using HEK-293T cells tran-
siently expressing GHS-R1a-YFP and increasing amounts
of GHS-R1b-Rluc or CB1R-Rluc or expressing increasing
amounts of GHS-R1b-Rluc. Cells were washed three times with
borate buffer (10 mM H3BO3 (pH 8.8) and 150 mM NaCl) and
incubatedwith 50g/ml sulfo-NHS-LC-biotin (Thermo Fisher
Scientific, Halethorpe, MD) in borate buffer for 5 min at room
temperature. Cells were then washed three times in borate
buffer and again incubatedwith 50g/ml sulfo-NHS-LC-biotin
in borate buffer for 10 min at room temperature, followed by
addition of 13 mM NH4Cl for 5 min to quench the remaining
biotin. Cells were washed in PBS, disrupted with three 10-s
strokes in a Polytron, and centrifuged at 16,000 g for 30 min.
The pellet was solubilized in ice-cold radioimmune precipita-
tion assay buffer (50 mM Tris-HCl, 1% Triton X-100, 0.2% SDS,
100mMNaCl, 1 mM EDTA, and 0.5% sodium deoxycholate) for
30 min and centrifuged at 16,000 g for 20 min. The superna-
tant was incubated with 80 l streptavidin-agarose beads (Sig-
ma-Aldrich) for 1 h with constant rotation at 4 °C. Beads were
washed three times with ice-cold lysis buffer and aspirated to
dryness with a 28-gauge needle. Subsequently, 50 l of SDS-
PAGE sample buffer (8 M urea, 2% SDS, 100 mM dithiothreitol,
and 375mMTris (pH 6.8)) were added to each sample. Proteins
were dissociated by heating to 37 °C for 2 h and resolved by
SDS-polyacrylamide gel electrophoresis in 10% gels and immu-
noblotted as described above.
RT-PCR Assay—Total cellular RNA was isolated from neu-
ronal cultures using a QuickPrep total RNA extraction kit
(AmershamBiosciences, Piscataway,NJ). Total RNA (1g)was
reverse-transcribed by random priming using the RNase H
minus, point mutant, Moloney murine leukemia virus reverse
transcriptase, following the protocol for two-step RT-PCR pro-
vided by Promega (Madison, WI). The resulting single-
stranded cDNA was used to perform PCR amplification for
GHS-R1a and GHS-R1b and GAPDH as an internal control of
the PCR technique using TaqDNA polymerase (Promega).
A rat GHS-R1a and GHS-R1b common forward primer (5-
GCTCTTCGTGGTGGGCATCT-3) was used. To amplify
GHS-R1a, the 5-GAGAAGGATTCAAATCCTAGCA-3
reverse primer was used, corresponding to a nucleotide
sequence coding for transmembrane domain 7, not present in
GHS-R1b. To amplify GHS-R1b, the 5-TCAGCGGGTGCCA-
GGACTC-3 reverse primer was used, corresponding to a
nucleotide sequence coding for the fiveTMdomain not present
in GHS-R1a. To amplify GAPDH, the primers used were 5-
CATCCTGCACCACCAACTGCTTAG-3 (forward) and 5-
GCCTGCTTCACCACCTTCTTGATG-3 (reverse). RNA
without reverse transcriptions did not yield any amplicons,
indicating that there was no genomic DNA contamination.
DynamicMass Redistribution (DMR) Label-freeAssays—Cell
signaling was explored using an EnSpire multimode plate
reader (PerkinElmer Life Sciences) by a label-free technology.
Refractive waveguide-grating optical biosensors, integrated in
384-well microplates, allow extremely sensitive measurements
of changes in local optical density in a detecting zone up to 150
nm above the surface of the sensor. Cellular mass movements
induced upon receptor activation were detected by illuminat-
ing the underside of the biosensor with polychromatic light and
measured as changes in wavelength of the reflectedmonochro-
matic light that is a sensitive function of the index of refraction.
The magnitude of this wavelength shift (in picometers) is
directly proportional to the amount of DMR. Briefly, HEK-
293T cells or neurons were seeded in 384-well sensor micro-
plates to obtain 70–80% confluent monolayers. Prior to the
assay, cells were washed twice with assay buffer (Hanks’ bal-
anced salt solution with 20 mM HEPES (pH 7.15)) and incu-
bated for 2 h in the reader at 24 °C in 30l/well of vehicle (assay
buffer with 0.1% DMSO). Hereafter, the sensor plate was
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scanned, and a baseline optical signature was recorded before
adding 10l of test compound dissolved in vehicle. Then, DMR
responses were monitored for at least 5000 s. Kinetic results
were analyzed using EnSpire workstation software v. 4.10.
cAMPAccumulation—Homogeneous time-resolved fluores-
cence energy transfer assays were performed using the Lance
Ultra cAMP kit (PerkinElmer Life Sciences). The optimal cell
density was first established for an appropriate fluorescent sig-
nal bymeasuring the time-resolved FRET signal as a function of
forskolin concentration using different cell densities. Forskolin
dose-response curves were related to the cAMP standard curve
to establish which cell density provides a response that covers
most of the dynamic range of the cAMP standard curve. 5000
HEK-293T cells or neurons/well in 384-well microplates grow-
ing in medium containing 50 M zardeverine were pretreated
with the antagonists or the corresponding vehicle at 25 °C for
20 min and stimulated with agonists for 15 min before adding
0.5 M forskolin or vehicle and incubating for an additional
15-min period. Fluorescence at 665 nm was analyzed on a
PHERAstar Flagship microplate reader equipped with an
homogeneous time-resolved fluorescence energy transfer opti-
cal module (BMG Labtech).
Intracellular Calcium Release—Cells were co-transfected
with the cDNA for the indicated receptors and 3g ofGCaMP6
calcium sensor (10) using the Lipofectamine 2000 (Thermo
Fisher Scientific)method. 48 h after transfection, 150,000HEK-
293T cells/well in 96-well black, clear-bottommicrotiter plates
were incubated with Mg2-free Locke’s buffer (pH 7.4) (154
mMNaCl, 5.6 mMKCl, 3.6 mMNaHCO3, 2.3 mMCaCl2, 5.6 mM
glucose, and 5 mM HEPES) supplemented with 10 M glycine,
and receptor ligands were added as indicated. The fluorescence
emission intensity of GCaMP6 was recorded at 515 nm upon
excitation at 488 nm on the EnSpire multimode plate reader
for 335 s every 15 s and 100 flashes/well.
Arrestin Recruitment Assays—Arrestin recruitment was
determined using BRET experiments as described above in
HEK-293T cells expressing the cDNA corresponding to -ar-
restin-2-Rluc (1 g transfected), GHS-R1a-YFP (1.5 g trans-
fected) alone or with GHS-R1b (0.05–0.5 g transfected) after
the indicated treatment with ligands.
ERK1/2 Phosphorylation—HEK-293T cells (30,000 cells/well
in 96-well plates) were treated with vehicle or the indicated
ligand for the indicated time and were lysed by the addition of
ice-cold lysis buffer (50 mM Tris-HCl (pH 7.4), 50 mMNaF, 150
mMNaCl, 45 mM -glycerophosphate, 1% Triton X-100, 20 M
phenyl-arsine oxide, 0.4 mM NaVO4, and protease inhibitor
mixture). Cellular debris was removed by centrifugation at
13,000 g for 5min at 4 °C, and the protein was quantified by the
FIGURE 1. GHS-R1b modulates plasma membrane expression of GHS-R1a in HEK-293T cells. A–C, confocal microscopy images of HEK-293T cells trans-
fected with GHS-R1a-YFP cDNA (1.5 g), GHS-R1b-Rluc (0.5 g), or both. GHS-R1a-YFP was identified by its own fluorescence (green) and GHS-R1b-Rluc by a
monoclonal anti-Rluc primary antibody and a cyanine-3-conjugated secondary antibody (red).C, colocalization of both receptors is shown in yellow. Cell nuclei
were stainedwith Hoechst (blue). Scale bars 10m.D, cAMPwas determined in HEK-293T cells transfectedwith cDNA (1.5g) from the indicated receptors
or fusion proteins. Cells were exposed for 15 min to vehicle or ghrelin (100 nM) in the presence of forskolin (0.5 M). Values are means S.E. of three to four
experiments and expressed as decreases (percent) versus forskolin alone (100%, dotted line). No statistical differences between differently transfected cells
were found by ANOVA followed by Bonferroni’s corrections (p 0.05). E–G, biotinylation experiments were performed in HEK-293T cells co-transfected with
GHS-R1a-YFP cDNA (1g) and increasing amounts of GHS-R1b-Rluc cDNA (0–0.6g) or GHS-R1b-Rluc cDNA alone (0.5g) (E), GHS-R1a-YFP cDNA (1g) and
increasing amounts of CB1R-Rluc cDNA (0–1g) (F), or increasing amounts of GHS-R1b-Rluc cDNA (0.05–0.6g) (G). Quantification of immunoreactive bands
from four to six independent experiments is shown. Values representmean S.E. of the percentage of GHS-R1a-YFPmembrane expression versus control cells
(cells not expressingGHS-R1b-Rluc or CB1R-Rluc) (E and F) or thepercentageofGHS-R1b-Rlucmembrane expression versus control cells (non-transfected cells)
(G). Statistical differences of differently transfected cells were analyzed by ANOVA followed by Bonferroni’s corrections. *, p	 0.05; ***, p	 0.001 compared
with control cells. Representative Western blotting analyses are shown in the bottom panels.
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bicinchoninic acid method using bovine serum albumin dilutions
as the standard. Equivalent amounts of protein (10 g) were sep-
arated by electrophoresis (10% SDS-polyacrylamide gel) and
transferredontoPVDFfluorescencemembranes.Themembranes
were probed with a mixture of a mouse anti-phospho-ERK1/2
antibody (1:2500, Sigma-Aldrich) and a rabbit anti-ERK1/2
antibodythat recognizesbothphosphorylatedandnon-phosphor-
ylated ERK1/2 (1:40,000, Sigma-Aldrich), and bands were visual-
ized by the addition of a mixture of IRDye 800 (anti-mouse) anti-
body (1:10,000, Sigma-Aldrich) and IRDye 680 anti-rabbit
antibody (1:10,000, Sigma-Aldrich) and scanned by the Odyssey
infrared scanner. Bands densities were quantified using the scan-
ner software, and the level of phosphorylated ERK1/2 isoforms
was normalized for differences in loading using the total ERK1/2
protein band intensities.
Results
GHS-R1b-mediated Modulation of GHS-R1a Expression at
the Plasma Membrane in Transfected HEX-293T Cells—The
role of GHS-R1b on GHS-R1a expression in the plasma mem-
brane was evaluated first by analyzing GHS-R1a expression by
immunocytochemistry and confocal microscopy in HEK-293T
cells transfected with cDNA of GHS-R1a fused to YFP (GHS-
R1a-YFP, 1 g), GHS-R1b fused to Rluc (GHS-R1b-Rluc, 0.5
g), or both. Both GHS-R1a-YFP (Fig. 1A, identified by its own
fluorescence) and GHS-R1b-Rluc (Fig. 1B, identified by anti-
Rluc and secondary Cy3 antibodies, see “Experimental Proce-
dures”), when expressed alone, could be detected in intracellu-
lar structures and at the plasma membrane level. Some degree
of co-localization could be observed upon GHS-R1a-YFP and
GHS-R1b-Rluc co-transfection (Fig. 1C). Fused receptors
retained the same degree of functionality compared with non-
fused receptors (Fig. 1D). Biotinylation experiments using a
non-membrane permeable biotin were performed to provide a
more accurate determination of receptor expression at the
plasma membrane. HEK-293T cells were co-transfected with
GHS-R1a-YFP cDNA (1 g) and increasing amounts of GHS-
R1b-Rluc cDNA (0, 0.1, 0.2, 0.3, or 0.6 g) or only with GHS-
R1b-Rluc cDNA (0.3 g). Total expression of GHS-R1a-YFP
(YFP fluorescence, 20,000  2000 units) did not significantly
change by increasing the expression of GHS-R1b-Rluc (Rluc
luminescence, 10,000–300,000 units). To determine the rela-
FIGURE 2.GHS-R1bmodulates GHS-R1a signaling detected byDMR in HEK-293T cells.DMRwas determined in HEK-293T cells transfectedwith GHS-R1a-
YFP cDNA (1g) (A and B) or co-transfected with GHS-R1a-YFP cDNA (1g) and increasing amounts of GHS-R1b-Rluc cDNA (0.05–0.6g) to obtain a 0.5, 1.4,
and 5GHS-R1b-Rluc/GHS-R1a-YFP ratio (C andD). Cells were pretreated overnightwith vehicle (A, C, andD) or with PTX (10 ng/ml), CTX (100 ng/ml), or theGq
inhibitor YM254890 (YM, 1 M) (B), followed by treatment (15 min) with vehicle or the GHS-R1a antagonist YIL781 (2 M) and activated with increasing
concentrations of ghrelin (10, 30, and 100 nM; A, C, and D) or with 30 nM ghrelin (B). Representative picometer (pm) shifts of reflected light wavelength versus
time curves are shown in A and C. Each curve represents the mean of an optical trace experiment carried out in triplicate. B, maximum responses at 500 s are
derived from the corresponding picometer shifts of reflected lightwavelength versus time curves.D, maximum responses at 500 s induced by different ghrelin
concentrations (10–100nM) are compared forGHS-R1b-Rluc/GHS-R1a-YFP ratios from0–5. Values are derived from the curves inA andC. Statistical differences
of the effect of ghrelin between cells treated with PTX compared with vehicle-treated cells (B) or in cells transfected with different GHS-R1b/GHS-R1a ratios
compared with cells only expressing GHS-R1a (D) were analyzed by ANOVA followed by Bonferroni’s corrections. *, p	 0.05; **, p	 0.01; ***, p	 0.001.
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tive expression of GHS-R1b with respect to GHS-R1a (GHS-
R1b/GHS-R1a) in transfected cells, we performed parallel
experiments in which HEK-293T cells were transfected with
increasing amounts of GHS-R1a-YFP cDNA (up to 1.5 g) or
GHS-R1b-YFP cDNA (up to 0.6 g), and the relative total
expression of receptors was calculated by Western blotting
using an anti-YFP antibody. Linearity of transfected cDNA ver-
sus the Western blotting signal or versus fluorescence was
obtained in both cases (transfected cDNA inmicrograms versus
fluorescence values in arbitrary units gave linear plots with
slopes of 0.885 and 0.099, respectively), which allowed the accu-
rate determination of the relative GHS-R1b/GHS-R1a expres-
sion ratio. Co-transfection with 1 g of GHS-R1a-YFP and 0,
0.1, 0.2, 0.3, or 0.6 g of GHS-R1b-YFP gave GHS-R1b/GHS-
R1a ratios of 0, 0.25, 0.5, 1.4, and 5, respectively. Biotinylation
experiments demonstrated that transfected GHS-R1a was
always present in the plasma membrane, with or without co-
transfection with GHS-R1b, and that co-transfection with
GHS-R1b resulting in GHS-R1b/GHS-R1a ratios from 0.25–5
led to an inverted U shape in the relative expression of GHS-
R1a in the plasmamembrane (Fig. 1E). As a negative control, no
changes in GHS-R1a expression at the plasma membrane were
detected upon co-transfection with increasing amounts of
CB1R-Rluc cDNA (Fig. 1F, the CB1R/GHS-R1a expression
ratio was calculated as above using the slope value of 0.139
corresponding to linear plots of transfected CB1R-YFP cDNA
in micrograms versus fluorescence values in arbitrary units).
Furthermore, biotinylation also demonstrated a linear increase
in the plasmamembrane expression of GHS-R1b upon increas-
ing transfected amounts of GHS-R1b-YFP cDNA (Fig. 1G).
These data indicate that GHS-R1b differentially modulates
GHS-R1a expression at the plasma membrane level as a func-
tion of GHS-R1b/GHS-R1a expression ratio.
GHS-R1b-mediated Modulation of GHS-R1a Signaling in
Transfected HEK-293T Cells—The role of GHS-R1b on GHS-
R1a signaling was evaluated in HEK-293T cells expressing the
same amount of GHS-R1a-YFP (fluorescence, 20,000  2000)
and increasing amounts of GHS-R1b-Rluc (0–5 GHS-R1b/
GHS-R1a ratio). First, the effect of GHS-R1b on GHS-R1a sig-
nalingwas determinedwith aDMR label-free assay (see “Exper-
imental Procedures”), which can detect ligand-induced
changes in light diffraction in the bottom 150 nm of a cell
monolayer mostly dependent on G protein-dependent signal-
ing (12). Ghrelin (10, 30, and 100 nM) induced dose- and time-
dependent signaling in cells only transfected with GHS-R1a-
YFP, which was inhibited by the GHS-R1a antagonist YIL781
FIGURE 3. Lack of functionality of GHS-R1b when expressed without GHS-R1a. DMR (A), cAMP accumulation (B), cytosolic Ca2 increases (C),  arrestin-2
recruitment (D), and ERK1/2 phosphorylation (E) were determined in HEK-293T cells transfected with 0.4g of GHS-R1b-Rluc cDNA. The cells were pretreated
(15min) with vehicle or the GHS-R1a antagonist YIL781 (YIL, 2M), followed by activation (15min) with increasing concentrations of ghrelin in the absence (A
and C–E) or presence (B) of 0.5 M forskolin (FK). Values are means S.E. of four to five experiments. pm, picometer.
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(Fig. 2A). Ghrelin-induced DMR was completely blocked by
pertussis toxin (PTX) but not by cholera toxin (CTX) or the Gq
inhibitor YM254890 (Fig. 2B), indicating a predominant ghre-
lin-mediated Gi/o protein coupling to GHS-R1a in HEK-293T
cells. As expected, ghrelin did not produce any significant effect
in cells only expressing GHS-R1b-Rluc (Fig. 3A). The ghrelin-
mediated DMR signal was then analyzed upon three different
GHS-R1b/GHS-R1a expression ratios: 0.5, 1.4, and 5. At a
GHS-R1b/GHS-R1a expression ratio of 0.5, ghrelin was signif-
icantly more efficient than when the cells were only transfected
with GHS-R1a (Fig. 2, C and D). Taking also into account the
results of biotinylation experiments, these results suggest that
low relative GHS-R1b expression potentiates ghrelin-induced
Gi/o protein-mediated signaling by facilitating GHS-R1a traf-
ficking to the plasma membrane. However, progressively
increasing the relative expression of GHS-R1b led to a progres-
sive decrease in signaling thatwent down to an almost complete
lack of effect of ghrelin with a GHS-R1b/GHS-R1a expression
ratio of 5 (Fig. 2, C and D). This switch from facilitation to
inhibition of ghrelin-induced Gi/o protein-mediated signaling
cannot be explained by a GHS-R1b-mediated modulation of
GHS-R1a trafficking because plasma membrane expression of
GHS-R1a was the same at the highest GHS-R1b/GHS-R1a
expression ratio than in cells not co-transfected with GHS-R1b
(Fig. 1E). According to the predominant coupling to Gi/o pro-
tein, ghrelin dose-dependently decreased forskolin-induced
cAMP accumulation in cells only expressing GHS-R1a (Fig.
4A). Again, this effect was not observed in cells only trans-
fected with GHS-R1b (Fig. 3B), was inhibited by YIL781 (Fig.
4A), and was dependent on the GHS-R1b/GHS-R1a expres-
sion ratio, with ghrelin being more efficient, similarly effi-
cient, and inefficient at expression ratios of 0.5, 1.4, and 5,
respectively, compared with cells only transfected with
GHS-R1a (Fig. 4B).
Ghrelin also induced a dose-dependent increase in cytosolic
Ca2 (Fig. 5, A and B),  arrestin-2 recruitment (Fig. 5C), and
ERK1/2 phosphorylation (Fig. 5D) in HEK-293T cells only
transfected with GHS-R1a. All measured ghrelin-activated sig-
naling pathways were also inhibited by YIL781 (Fig. 5), and they
were not observed in cells only transfected with GHS-R1b (Fig.
3, C–E). Importantly, these three signaling mechanisms were
dependent on the GHS-R1b/GHS-R1a expression ratio (Fig. 5).
As observed with DMR and cAMP accumulation experiments,
at GHS-R1b/GHS-R1a expression ratios of 0.5, 1.4, and 5, ghre-
lin was more efficient, similarly efficient, and significantly less
efficient or inefficient, respectively, compared with cells only
transfected with GHS-R1a (Fig. 5).
Homodimers andHeterotetramers ofGHS-R1aandGHS-R1b
in HEK-293T-transfected Cells—Biotinylation and signaling
experiments therefore did not support a preferential intracel-
lular localization of GHS-R1b and GHS-R1a retention upon
intracellular heteromerization with GHS-R1b as the basis for a
dominant negative effect of GHS-R1b onGHS-R1a function (6,
7). Our results instead fit with a negative effect of GHS-R1b on
FIGURE4.GHS-R1bmodulatesGHS-R1a-mediated inhibitionofadenylyl cyclase inHEK-293Tcells. cAMPaccumulationwasdetermined inHEK-293Tcells
transfectedwith GHS-R1a-YFP cDNA (1g) (A) or co-transfectedwith GHS-R1a-YFP cDNA (1g) and increasing amounts of GHS-R1b-Rluc cDNA (0.05–0.6g)
to obtain a 0.5, 1.4, and 5 GHS-R1b-Rluc/GHS-R1a-YFP ratio (B). Cells were incubated overnight with vehicle or PTX (10 ng/ml) or for 2 h with CTX (100 ng/ml)
andpretreated (15min)with vehicle or theGHS-R1a antagonist YIL781 (2M), followedby activation (15min)with ghrelin in the absence or presence of 0.5M
forskolin (FK). Values are means S.E. of five to six experiments per treatment and expressed as decreases of forskolin-induced cAMP accumulation (100%,
dotted line). Statistical differences of the effect of differently treated cells under different transfection conditions were analyzed by ANOVA followed by
Bonferroni’s corrections. *, p	 0.05; ***, p	 0.001 compared with the effect of forskolin alone.
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GHS-R1a signaling upon heteromerization in the plasma
membrane (5). Because GPCR homodimers seem to be a pre-
dominant species and oligomeric entities are viewed as multi-
ples of dimers (13), we also investigated the possibility of
homodimerization of GHS-1b and heteromerization of GHS-
R1a and GHS-R1b homodimers. Saturable BRET curves were
obtained in HEK-293T cells expressing a constant amount of
GHS-R1a-Rluc and increasing amounts ofGHS-R1a-GFP2 (Fig.
6A, BRETmax of 82 6mBU and BRET50 of 55 13mBU) or a
constant amount of GHS-R1b-Rluc and increasing amounts of
GHS-R1b-YFP (Fig. 6B, BRETmax of 124 12mBUandBRET50
of 52 16 mBU), strongly suggestive of homodimerization. As
negative controls, linear plots with low BRET values were
obtained using either CB1R-Rluc (Fig. 6A) or CRF1-Rluc (Fig.
6B). SRET assay was then used to evaluate the possibility of
direct interactions between three receptor molecules, either
two GHS-R1a and one GHS-R1b or two GHS-R1b and one
GHS-R1a, as depicted in Fig. 6, C andD. In this assay, Rluc was
fused to one of the receptor units to act as a BRET donor, GFP2
was fused to a second receptor unit to act as a BRET acceptor
and FRET donor, and YFP was fused to the third receptor unit
to act as a FRET acceptor. The cDNA constructs were trans-
fected in HEK-293T cells, and YFP emission was determined
after adding DeepBlueC as luciferase substrate. Positive SRET
saturation curves were obtained with transfection of a constant
amount of GHS-R1b-Rluc and GHS-R1a-GFP2 and increasing
amounts of GHS-R1a-YFP (Fig. 6C) or increasing amounts of
GHS-R1b-YFP (Fig. 6D), with SRETmax values of 222 18mSU
and 40 5 mSU and SRET50 values of 48 14 mSU and 72
20mSU, respectively. As negative controls, linear plotswith low
SRETvalueswere obtainedwhenCB1R-Rlucwas transfected as
the BRET donor of GHS-R1a or GHS-R1b FRET pairs (Fig. 6,C
FIGURE 5.GHS-R1bmodulates GHS-R1a-mediated cytosolic Ca2 increase, arrestin-2 recruitment, and ERK1/2 phosphorylation. A and B, HEK-293T
cells were transfected with GHS-R1a-YFP cDNA (1 g) or co-transfected with GHS-R1a-YFP cDNA (1 g) and increasing amounts of GHS-R1b-Rluc cDNA
(0.05–0.6g) to obtain a 0.5, 1.4, and 5 GHS-R1b-Rluc/GHS-R1a-YFP ratio. A, representative intracellular curves of Ca2 release over time. B, values of maximal
Ca2 release (means S.E., n 4–6) induced by 30 nM ghrelin were derived from the curves obtained at the different GHS-R1b-Rluc/GHS-R1a-YFP ratios. C,
-arrestin-2 recruitment (means  S.E., n  5–7) was measured by BRET experiments in cells transfected with 1 g of -arrestin-2-Rluc cDNA and 1 g of
GHS-R1a-YFP cDNA in the absence or the presence of GHS-R1b cDNA (0.05–0.6 g). In all cases, cells were pretreated (15 min) with vehicle or the GHS-R1a
antagonist YIL781 (2 M), followed by activation with ghrelin (30, 100, or 300 nM). D, ERK1/2 phosphorylation from the same transfected cell groups and
treatments as in C, expressed as a percentage over values found in non-transfected cells (means S.E., n 5–7). RepresentativeWestern blotting analyses are
shown in the bottom panel. Statistical differences of the effect of different GHS-R1b/GHS-R1a ratios under different treatment conditions were analyzed by
ANOVA followed by Bonferroni’s corrections. *, p	 0.05 compared with cells only expressing GHS-R1a.
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and D). These results show the ability of GHS-R1a and GHS-
R1b to assemble as heterotrimers and possibly heterotetramers.
Support for heterotetramer formation was obtained by using
BRET with double BiLC and BiFC assays (15, 16). In this assay,
the twoBRET sensors, the donor Rluc8 (amore efficient variant
of Rluc) and the acceptor YFPVenus (amore efficient variant of
YFP), are split into two hemiproteins, with each split sensor
being fused to one of the four putative interacting receptors.
BRET indicates reconstitution of both sensors and close prox-
imity of the four receptors. A saturable BRET curve (BRETmax
of 111  10 mBU and BRET50 of 7  2 mBU) was detected in
HEK-293T cells co-transfected with equal amounts of GHS-
R1a-cRluc and GHS-R1b-nRluc cDNAs and increasing
amounts of GHS-R1a-cYFP and GHS-R1b-nYFP cDNAs (Fig.
6E). Negative controls were cells transfected with adenosine
A1R-cRluc cDNA instead of GHS-R1a-cRluc cDNA (Fig. 6E).
Collectively, these results indicate that GHS-R1a andGHS-R1b
receptors can form oligomeric complexes that include hetero-
mers of homodimers.
Differential GHS-R1b-mediated Modulation of GHS-R1a
Signaling in Rat Striatal and Hippocampal Neurons—The sig-
nificance of GHS-R1a-mediated signaling and its modulation
by heteromerization with GHS-R1b was then addressed in pri-
mary neuronal cultures from the striatum and hippocampus,
brain areas that express functional GHS-R1a receptors (3, 4).
The relative expression of both GHS-R1a and GHS-R1b, deter-
mined by RT-PCR, was higher in striatal compared with hip-
pocampal primary cultures (Figs. 7A). DMR was first analyzed
to evaluate ghrelin-mediated signaling, and a dose-dependent
response was obtained in both primary cultures (Fig. 7, B–D).
Ghrelin was more potent and efficient in striatal than in hip-
pocampal neurons, and its effects were counteracted by YIL781
in both preparations (Fig. 7, B–D). As shown in Fig. 7A, the
relative expression of GHS-R1b was higher than GHS-R1a in
striatal neurons, whereas the opposite, a higher relative expres-
sion of GHS-R1a than GHS-R1b, was observed in hippocampal
neurons. Therefore, from the results obtained in HEK-293T
cells, we anticipated that an increase in GHS-R1b expression
could lead to opposite effects in hippocampal and striatal neu-
rons. Indeed, in hippocampal primary cultures, transfection
with increasing amounts of GHS-R1b cDNA (0.1 and 0.5 g)
led to a progressive significant increase in the efficacy of ghre-
lin-induced DMR (Fig. 8, A and C), whereas, in striatal primary
cultures, GHS-R1b transfection led to the opposite effect (Fig.
8, B and C). By analyzing another signaling readout, cAMP
accumulation, unexpected results were obtained compared
with HEK-293T cells in both hippocampal and striatal primary
cultures. Ghrelin produced an increase in cAMP production
with an inverted U-shaped dose-response (maximal effect at
about 100 nM), indicating an agonist-induced desensitization
FIGURE 6.Heterotetramers of GHS-R1a andGHS-R1bhomodimers inHEK-293T cells. A and B, GHS-R1a andGHS-R1b homodimerswere detected by BRET
saturation experiments in HEK-293T cells co-transfected with GHS-R1a-Rluc cDNA (1.5g) and increasing amounts of GHS-R1a-GFP2 cDNA (0.5–3g) (A) or a
constant amount of GHS-R1b-Rluc cDNA (0.3 g) and increasing amounts of GHS-R1b-YFP (0.05–0.6 g) (B). As negative controls, linear and low BRET values
were obtained by transfecting the cDNA corresponding to either cannabinoid receptor CB1R-Rluc (0.5 g, A) or the corticotropin-releasing factor receptor
CRFR1-Rluc (0.3 g, B) as BRET donors. C and D, positive SRET saturation curves were obtained in HEK-293T cells co-transfected with a constant amount of
GHS-R1b-Rluc cDNA (0.4g) andGHS-R1a-GFP2 cDNA (1.5g) and increasingamountsofGHS-R1b-YFPcDNA (0.5–3g,C) orGHS-R1a-YFPcDNA (0.05–0.5g,
D). As SRET negative controls, linear and low SRET values were obtainedwhen CB1R-Rluc cDNA (0.4g) was transfected as BRET donor of GHS-R1a or GHS-R1b
FRET pairs. E, the BiLFC saturation curve was obtained in HEK-293T cells co-transfected with equal amounts of cDNA corresponding to GHS-R1a-cRluc and
GHS-R1b-nRluc (1.5g) and increasing amounts of GHS-R1a-cYFP and GHS-R1b-nYFP cDNAs (0.5–2.5g for each). As a negative control, linear and low BiLFC
were obtained in cells transfectedwith adenosine A1R-cRluc cDNA (0.2g) instead of GHS-R1a-cRluc cDNA. The relative amounts of BRET or SRET are given as
a function of 100 the ratio between the fluorescence of the acceptor and the luciferase activity of the donor. BRET and SRET are expressed asmilliBRET units
or milliSRET units (mSU) and given as the means S.D. of four to five experiments grouped as a function of the amount of BRET or SRET acceptor.
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effect (Fig. 8, D and E). This effect was blocked by YIL781 in
both preparations (Fig. 8,D and E, black columns). The same as
for DMR, in hippocampal and striatal primary cultures, trans-
fection with increasing amounts of GHS-R1b cDNA (0.1 and
0.5 g) led to a progressive significant increase and decrease,
respectively, in the effect of ghrelin-induced cAMP accumula-
tion (Fig. 8, D and E). The results also showed that, in neurons,
GHS-R1b can positively or negativelymodulateGHS-R1a func-
tion depending on the endogenous relative GHS-R1b/GHS-
R1a expression ratio.
Dopamine D1R Interacts with GHS-R1a-GHS-R1b Hetero-
mers, Promoting Coupling to Gs/olf Protein—Previous studies
have suggested that GHS-R1a-mediated signaling depends
mostly on Gq coupling, although, in HEK-293T cells in this
study, evidence for Gi/o coupling has also been obtained (see
“Discussion”). Similarly, ghrelin-induced cAMP-PKA signaling
has also been reported but suggested to be independent of Gs/olf
proteins (see “Discussion”). The G protein subtype involved in
ghrelin-induced cAMP accumulation in striatal and hippocam-
pal neurons in culture was first investigated by using the Gs/olf
toxin CTX, the Gi/o toxin PTX, and the Gq protein inhibitor
YM254890. CTX, but not PTX or YM254890, prevented ghre-
lin-induced cAMP in both preparations (Fig. 9, A and B), iden-
tifyingGs/olf as predominant G proteins coupled toGHS-R1a in
neurons. Although CTX increased the basal levels of cAMP by
about 2- to 3-fold, this cannot explain an apparent inhibition of
the effect of ghrelin because of saturation on the activation of
adenylyl cyclase because, under the same experimental condi-
tions, forskolin increased cAMP levels by 10-fold (data not
shown). A possible explanation for the unexpected preferential
coupling of GHS-R1a to Gs/olf in neurons versus Gi/o in HEK-
293T cells could be the presence in neuronal primary cultures
of additional receptors that could interact with GHS-R1a or
GHS-R1b. Indeed, dopamine D1R is a canonical mediator of
adenylyl cyclase activation that has been reported to hetero-
merize with GHS-R1a (17, 18). We then investigated its possi-
ble involvement in ghrelin-mediated cAMP accumulation in
neurons in culture. In fact, the D1R antagonist SCH23390 (1
M), but not the dopamine D2R antagonist raclopride (1 M),
blocked ghrelin-induced cAMP accumulation in striatal but
not hippocampal neurons in culture (Fig. 9,C andD). That D1R
co-expression can promote a switch in G protein coupling of
GHS-R1a from Gi/o to Gs/olf was then demonstrated in HEK-
293T cells transfected with GHS-R1b-Rluc cDNA (0.2 g),
GHS-R1a-YFP cDNA (1 g, GHS-R1b/GHS-R1a ratio of 1.4)
and D1R cDNA (0.4 g, Fig. 10A), or D2R cDNA (0.4 g, Fig.
10B). In the presence of D1R, both ghrelin (100 nM) and the
D1R agonist SKF81297 (100 nM) increased cAMP production,
an effect that was blocked by CTX but not by PTX or the Gq
inhibitor YM254890 (Fig. 10A). In the presence of D2R, both
ghrelin (100 nM) and the D2R agonist quinpirole (1 M)
decreased cAMPproduction, an effect thatwas blocked by PTX
but not by CTX or the Gq inhibitor YM254890 (Fig. 10B). Fig.
10Cdemonstrates agonist selectivity at the concentrations used
in cAMP experiments using cells only transfected with single
receptors. In cells transfected with GHS-R1a, GHS-R1b, and
D1R, co-activation of GHS-R1a and D1R with ghrelin (100 nM)
and SKF81297 (100 nM) did not produce an additive or syner-
gistic effect (Fig. 10D), but blockade of either receptor with the
D1R antagonist SCH23390 (1 M) or the GHS-R1a antagonist
YIL781 (1 M) completely counteracted cAMP accumulation
induced by both ghrelin and SKF81297 (Fig. 10D). Because the
FIGURE 7. Differential expression of GHS-R1a and GHS-R1b in striatal and hippocampal neurons in culture. A, the relative expression of GHS-R1a and
GHS-R1b was determined by RT-PCR using primary cultures of rat hippocampal (white columns) and striatal (black columns) neurons. C and D, DMR was
determined in striatal (C) or hippocampal (D) neuronal primary cultures pretreated (30min)with vehicle or theGHS-R1a antagonist YIL781 (2M) and followed
by activation with ghrelin (30 or 100 nM). Representative picometer (pm) shifts of reflected light wavelength versus time curves are shown. Each curve
represents the mean of an optical trace experiment carried out in triplicate. B, maximum responses of DMR at 2000 s induced by ghrelin (30 or 100 nM) are
compared for striatal and hippocampal neuronal cultures. Values aremeans S.E. of five to seven experiments performedwith independent primary cultures.
Statistical differences of the expression of GHS-R1a and GHS-R1b and the effect of ghrelin between hippocampal compared with striatal cell cultures were
analyzed by ANOVA followed by Bonferroni’s corrections. **, p	 0.01; ***, p	 0.001.
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interactions between GHS-R1a and D1R ligands, particularly
the cross-antagonism (see “Discussion”), strongly suggested
oligomerization, we investigated this possibility with BRET
experiments. In HEK-293T cells transfected with a constant
amount of D1R-Rluc cDNA (0.4g) and increasing amounts of
GHS-R1a-YFP cDNA (0.2–1.5g) (Fig. 11A) or GHS-R1b-YFP
cDNA (0.1–0.6 g) (Fig. 11B), low and linear plots were
observed, consistent with nonspecific interactions. Similarly,
low BRET values were obtained (at a YFP/Rluc ratio of 100)
when cells where exposed to ghrelin, the D1R agonist
SKF81297, or both (100 nM in all cases, Fig. 11, C and D). Nev-
ertheless, a saturable BRET curve was obtained when cells were
transfected with D1R-Rluc cDNA (0.4 g), increasing amounts
ofGHS-R1b-YFP cDNA (0.1–0.6g), andGHS-R1a cDNA (0.8
g), with BRETmax and BRET50 values of 36 6mBU and 93
10 mBU, respectively (Fig. 11E, black line), indicating that D1R
specifically interacts with GHS-R1a-GHS-R1b heteromers. In
agreement, significant BRET values could only be obtained in
cells transfected with D1R-Rluc cDNA (0.4 g) and GHS-R1a-
GFP2 (1.0 g) when co-transfected with increasing amounts of
GHS-R1b cDNA (0.05–0.3 g) (Fig. 11F). BRET saturation
curves were also obtained in cells transfected with D1R-Rluc
cDNA (0.4 g), increasing amounts of GHS-R1b-YFP cDNA
(0.1 to 0.6 g), and GHS-R1a cDNA (0.8 g) and treated with
100 nM SKF81297 (Fig. 11E, red line; BRETmax and BRET50
values of 34 3 mBU and 25 11 mBU, respectively), 100 nM
ghrelin (Fig. 11E, green line; BRETmax and BRET50 values of
46 3mBU and 99 12mBU, respectively), or both (Fig. 11E,
blue line; BRETmax and BRET50 values of 52 3mBU and 39
9mBU, respectively). The significant increase inBRETmax upon
treatment with ghrelin indicates a facilitation of energy transfer
or an increase in heteromer formation, whereas the significant
decrease in BRET50 upon treatmentwith SKF81297 suggests an
increase in the affinity of the interaction between receptors.
Both effects, a significant increase in BRETmax and a significant
decrease in BRET50, were observed upon co-treatment with
ghrelin and SKF81297 (significant statistical differences in
BRETmax and BRET50 compared with control non-treated cells
were determined by ANOVA followed by Bonferroni’s correc-
tions: *, p 	 0.05 in all cases). If D1R can only interact with
GHS-R1a in the presence ofGHS-R1b, the absence ofGHS-R1b
should disclose the properties that are dependent onGHS-R1a-
GHR1b-D1R heteromerization. In fact, in cells transfectedwith
D1R but only co-transfected with GHS-R1a, ghrelin (100 nM)
did not produce cAMP accumulation, and YIL781 (1 M) did
not counteract cAMP accumulation induced by SKF81297 (100
nM) (Fig. 12). Together, the results from transfectedHEK-293T
cells provide a very plausible mechanism for the results
obtained in striatal cells in culture, demonstrating that GHS-
R1b determines the ability of GHS-R1a to form oligomeric
complexes with D1R, which allows ghrelin to activate Gs/olf
protein-mediated signaling.
FIGURE 8.GHS-R1b-mediatedmodulation ofGHS-R1a signaling in striatal andhippocampal neurons.A–C, DMRwas determined in rat hippocampal (A andC)
and striatal (B and C) primary cultures not transfected (black) or transfectedwith 0.1g (blue) or 0.5g (green) of GHS-R1b cDNA and activatedwith 100 nM ghrelin.
Representative picometer (pm) shifts of reflected light wavelength versus time curves are shown in A and B. Each curve represents the mean of an optical trace
experiment carriedout in triplicate.C, ghrelin-inducedmaximumresponses at 2000 s are compared for striatal andhippocampalneuronal culturesnot transfectedor
transfectedwith0.1or0.5gofGHS-R1bcDNA.Statisticaldifferencesbetweendifferently transfectedcells foreachtypeofculturewereanalyzedbyANOVAfollowed
byBonferroni’s corrections. *,p	 0.05; ***,p	 0.001 comparedwith non-transfected cells.D and E, cAMPaccumulationwas determined in rat hippocampal (D) and
striatal (E) primary cultures not transfected (black) or transfectedwith 0.1g (blue) or 0.5g (green) of GHS-R1b cDNA. Cells were pretreated (15min) with vehicle or
theGHS-R1a antagonist YIL781 (2M), followedby activation (15min)with increasingghrelin concentrations. Values aremeans S.E. of four to six experiments and
expressedaspercentageof values fromnon-stimulated cells (100%,dotted line). Statistical differencesbetweendifferently transfected cellswere analyzedbyANOVA
followed by Bonferroni’s corrections. *, p	 0.05; ***, p	 0.001 comparedwith non-transfected cells.
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FIGURE 9. Gs/olf-coupling of ghrelin receptors in striatal and hippocampal neurons. A and B, cAMP accumulation was determined in rat striatal (A) and
hippocampal (B) primary cultures incubated overnight with vehicle, PTX (10 ng/ml), or the Gq inhibitor YM254890 (YM, 1M) or for 2 h with CTX (100 ng/ml).
Cells were then treatedwith vehicle or ghrelin (100 nM). Values aremeans S.E. of three to four experiments and are expressed as percentage of the values of
vehicle-treated cells (100%, dotted line). C and D, cAMP accumulation was determined in rat striatal (A) and hippocampal (B) primary cultures pretreated (15
min) with vehicle, the D1R antagonist SCH23390 (SCH, 1 M), or the D2R antagonist raclopride (1 M), followed by treatment (15 min) with vehicle or ghrelin
(100 nM). Values aremeans S.E. of five to six experiments and are expressed as percentage of the values of vehicle-treated cells (100%, dotted line). Statistical
differences between differently treated cells were analyzed by ANOVA followed by Bonferroni’s corrections. *, p	 0.05; **, p	 0.01; ***, p	 0.001 compared
with vehicle-treated cells. &&, p	 0.01 compared with ghrelin-treated cells.
FIGURE 10. D1R promotes GHS-R1a-GHS-R1b heteromers coupling to Gs/olf protein. cAMP accumulation was determined in HEK-293T cells transfected
with GHS-R1b-Rluc cDNA (0.2 g), GHS-R1a-YFP cDNA (1 g), and D1R cDNA (0.4 g, A and D) or D2R cDNA (0.4 g, B) or single-transfected with the same
amountof the indicated receptors (C). Cellswere incubatedovernightwith vehicle, PTX (10ng/ml), or theGq inhibitor YM254890 (YM, 1M)or for 2hwithCTX
(100 ng/ml) and pretreated (15 min) with vehicle, the GHS-R1a antagonist YIL781 (YIL, 2 M), or the D1R antagonist SCH23390 (SCH, 1 M), followed by
activation (15 min) with ghrelin (100 nM), the D1R agonist SKF81297 (SKF, 100 nM), or the D2R agonist quinpirole (Quin, 1 M) alone or in combination in the
absence (A and D) or presence (B and C) of forskolin (FK, 0.5M). Values are means S.E. of six to eight experiments and expressed as percentage of values of
cells not treated with ghrelin (100%, dotted line). Statistical differences between differently treated cells were analyzed by ANOVA followed by Bonferroni’s
corrections. *, p	 0.05; **, p	 0.01 compared with vehicle-treated cells.
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Discussion
Previous studies about the role of the truncated ghrelin
receptor GHS-R1b only indicated a possible dominant negative
effect, which could depend on its ability to retain the full and
functional ghrelin receptor GHS-R1a in intracellular compart-
ments (6, 7) or to stabilize GHS-R1a in a non-signaling confor-
mation (5). This study does not support the intracellular mech-
anism as a main regulatory mechanism. Instead, it reveals a
novel and complexmodulatory role of GHS-R1b in the traffick-
ing and signaling of GHS-R1a. First, GHS-R1b facilitates GHS-
R1a trafficking to the plasmamembrane with an efficiency that
depends on a specific relative GHS-R1b/GHS-R1a expression
ratio.With further increases in theGHS-R1b/GHS-R1a expres-
sion ratio, this facilitation declines and disappears. Thus, higher
and probably non-physiological amounts of GHS-R1b seem to
be necessary to promote intracellular retention of GHS-R1a (6,
7). Second, GHS-R1b impairs GHS-R1a signaling upon oligo-
merization at the plasma membrane. The correlation between
the results obtained with biotinylation and signaling experi-
ments in HEK-293T cells demonstrates that the main factor
determining thepotencyofghrelin-inducedsignaling is thestoi-
chiometric relationship of both proteins in the plasma mem-
brane. Therefore, GHS-R1b can act as a dual modulator of
GHS-R1a function: low relative GHS-R1b expression potenti-
ates and high relative GHS-R1b expression inhibits GHS-R1a
function by facilitating GHS-R1a trafficking to the plasma
membrane and by exerting a negative allosteric effect on
GHS-R1a signaling, respectively. The ability of GHS-R1a
homodimers to oligomerize with one or several (at least two)
GHS-R1b protein molecules provides a frame for oligomeriza-
tion to be involved in this fine-tuning, stoichiometry-depen-
dent modulation of GHS-R1a function. Because GHS-R1a
seems to be the minimal functional unit (19), one possible sce-
nario is that one GHS-R1b molecule per one GHS-R1a
FIGURE 11. Selective heteromerization of D1RwithGHS-R1a-GH-R1b complexes. BRET experiments in HEK-293T cells transfectedwith a constant amount
of D1R-Rluc cDNA (0.4g) and increasing amounts of GHS-R1a-YFP cDNA (0.2–1.5g, A) or GHS-R1b-YFP cDNA (0.1–0.6g, B). BRET at a YFP/Rluc ratio of 100
was also determined in cells not activated or activated with ghrelin (100 nM), the D1R agonist SKF81297 (SKF, 100 nM), or both (C and D). E, BRET experiments
were performed in HEK-293T cells transfected with D1R-Rluc cDNA (0.4 g), GHS-R1a cDNA (0.8 g), and increasing amounts of GHS-R1b-YFP cDNA (0.1–0.6
g), not stimulated (black curve), or stimulated with SKF81297 (SKF, 100 nM, red curve), ghrelin (100 nM, green curve), or both (blue curve). F, BRET experiments
were performed inHEK-293T cells transfectedwithD1R-Rluc cDNA (0.4g), GHS-R1a-GFP
2 cDNA (1.0g), and increasing amounts of GHS-R1b cDNA (0.05–0.3
g). BRET values are given as a function of 100 the ratio between the fluorescence of the acceptor and the luciferase activity of the donor. BRET is expressed
as milliBRET units and given as the means  S.D. of four to six experiments grouped as a function of the amount of BRET acceptor. Statistical differences
between differently transfected cells were analyzed by ANOVA followed by Bonferroni’s corrections. *, p 	 0.05; **, p 	 0.01 compared with cells not
transfected with GHS-R1b.
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homodimer facilitates trafficking but not a negative allosteric
modulation of ghrelin, whereas two (or more) GHS-R1b mole-
cules would not facilitate trafficking but would allosterically
decrease ghrelin-mediated signaling.
To our knowledge, this is the first study that addresses the
modulatory role of GHS-R1b on GHS-R1a signaling in primary
neurons in culture that offers a more physiological model than
previously used mammalian transfected cell lines. The results
first indicate that endogenous relative expression of GHS-R1a
and GHS-R1b are in the same range in primary neuronal cul-
tures that in our experiments in HEK-293T transfected cells.
Significantly, from the experiments inHEK-293T cells, predict-
able changes in ghrelin-induced signaling were demonstrated
in striatal andhippocampal neurons in culture upon varying the
relative levels of expression of GHS-R1b. Progressively increas-
ing the expression of GHS-R1b in hippocampal and striatal cell
cultures led to an increase and decrease in ghrelin-induced sig-
naling, respectively, that depended on a respective initially low
and high relative GHS-R1a/GHS-R1b expression ratio.
In isolation, theGHS-R1a receptor has been shown to couple
to Gq proteins, resulting in activation of phospholipase C, ino-
sitol 1,4,5-trisphosphate, and Ca2mobilization (5, 19, 20), but
it has also been reported to produce signaling dependent on
pertussis toxin-sensitive Gi/o proteins (21, 22). Thus, ghrelin
seems to be able to activate different signaling pathways in a
tissue-specific manner. In pituitary GH cells, GHS-R1a seems
to couple preferentially to Gq, leading to stimulation of GH
release, whereas, in islet pancreatic  cells, it couples to Gi/o
proteins, and its activation leads to inhibition of insulin release
(23). It has also been reported that ghrelin can produce cAMP-
PKA signaling, although this is generally not attributed to its
canonically dependent stimulatoryGs protein (24–26). The use
of selective G protein toxins and inhibitors demonstrated a
preferential Gi/o coupling of the GHS-R1a-GHS-R1b complex
in HEK-293T cells and, unexpectedly, a preferential Gs/olf cou-
pling in both striatal and hippocampal neurons in culture. In
HEK-293T cells, the same modulation by GHS-R1b was
observed for GHS-R1a-mediated inhibition of adenylyl cyclase,
 arrestin-2 recruitment, ERK1/2 phosphorylation, and cytoso-
lic Ca2 increase. Although a canonical Gq-coupled signaling,
cytosolic Ca2 increase can also be induced by Gi-associated
-dependent mechanisms, as demonstrated in several mam-
maliancell lines, includingHEK-293cells (27,28).ERK1/2phos-
phorylation could then depend on a downstream effect of cyto-
solic Ca2 increase or  arrestin-2 recruitment (28, 29).
This study demonstrates that oligomerization with GHS-
R1b confers theGHS-R1a-GHS-R1b complex the ability to het-
eromerize with D1R, allowing ghrelin to signal through Gs/olf.
Thus, in HEK-293T cells transfected with GHS-R1a and GHS-
R1b, co-transfection of D1R promoted a switch of ghrelin-me-
diated signaling from Gi/o to Gs/olf signaling. A previous study
on transfected HEK-293 cells suggested that GHS-R1a can het-
eromerize and functionally interact with D1R but apparently
without concomitant interaction with GHS-R1b. The same
study also suggested that, within theGHS-R1a-D1Rheteromer,
ghrelin amplifies D1R signaling (17). A more recent study by
the same research group also suggests that GHS-R1a-D1R het-
eromerization allows D1R to couple and signal through Gq
proteins, again without the involvement of GHS-R1b (18).
However, our BRET experiments show that GHS-R1a-D1R
heteromerization depends on the presence of GHS-R1b in the
complex. In cells co-transfectedwithD1R,GHS-R1a, andGHS-
R1b, ghrelin (maximal effective concentration) does not poten-
tiate and, if anything, decreases cAMP accumulation induced
by SKF81297. Furthermore, a significant cross-antagonism, a
common biochemical property of receptor heteromers, was
also observed. This is the ability of an antagonist of one of the
protomers to counteract the signaling induced by an agonist of
the other protomer in a receptor heteromer (13). In cells trans-
fectedwithGHS-R1a, GHS-R1b, andD1R, both theD1R antag-
onist SCH23390 and theGHS-R1a antagonist YIL781were able
to block both SKF81297- and ghrelin-induced cAMP increases.
The cross-antagonism of SCH23390 on ghrelin-induced cAMP
accumulation was also observed in striatal but not in hip-
pocampal cells in culture. Furthermore, ghrelin-induced cAMP
accumulation in striatal cells was dependent on the relative
expression of GHS-R1b. The total correlation among the
results obtained in HEK-293T and striatal cells indicates the
presence of the same D1R-GHS-R1a-GHS-R1b complexes in
striatal cells. In the hippocampus, although evidence formolec-
ular and functional interactions between hippocampal GHS-
R1a and D1R have been reported recently (18), receptors other
than D1R might be responsible for coupling GHS-R1a-GHS-
R1b heteromers toGs-olf protein, suggesting that different com-
plexes containing GHS-R1a-GHS-R1b heteromers can be dif-
ferentially expressed in the brain.
In summary, GHS-R1b plays a much more active and com-
plex role in ghrelin-induced signaling than previously assumed.
This study indicates that the relative expression of GHS-R1b
not only determines the efficacy of ghrelin-induced, GHS-R1a-
mediated signaling but also determines the ability of GHS-R1a
to form oligomeric complexes with other receptors, promoting
profound qualitative changes in ghrelin-induced signaling.
FIGURE 12. Dependence on GHS-R1b for D1R-mediated modulation of
GHS-R1a signaling. cAMPaccumulationwas determined in cells transfected
with GHS-R1a-YFP cDNA (1.5 g) and D1R cDNA (0.5 g). Cells were treated
with vehicle, ghrelin (100 nM), or SKF 81297 (SKF, 100 nM) with and without
YIL781 (YIL, 2M) or SCH23390 (SCH, 1M). Values aremeans S.E. of four to
six experiments and are expressed as percentage values from cells only
treatedwith vehicle (100%, dotted line). Statistical differences betweendiffer-
ently treated cells were analyzed by ANOVA followed by Bonferroni’s correc-
tions. **, p 	 0.01; ***, p 	 0.001 compared with cells treated only with
vehicle.
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